Cross-institution positioning
Aug 6, 2026Reduction leaning. 2 accumulating, 1 reducing, 3 exited across 6 comparable institutions.
Source: Schedule 13 researchMOLINA HEALTHCARE, INC.
Latest stored close $196.93 as of Oct 9, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Reduction leaning. 2 accumulating, 1 reducing, 3 exited across 6 comparable institutions.
Source: Schedule 13 research2 increased/new, 0 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsRecent Forms 3/4/5 activity is available, with no non-amendment non-derivative SEC-coded P/S transactions in the rolling 90-day window. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/51 non-amendment material event in the last 90 days; Latest classified evidence: Results of operations / financial condition. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataRevenue -4.8% YoY; Net income -76.5% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 69% through its reported 52-week range; +17.5% over one year.
Source: Stored historical price seriesFiled Aug 6, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | BRASIER BARBARA L | AGrant, award, or other acquisition | Common Stock | 304 | $180.85 | Direct | Oct 2, 2026 |
| Oct 1, 2026 | SOISTMAN FRANCIS S JR | AGrant, award, or other acquisition | Common Stock | 304 | $180.85 | Direct | Oct 2, 2026 |
| Oct 1, 2026 | GROHOWSKI LEO P | AGrant, award, or other acquisition | Common Stock | 304 | $180.85 | Direct | Oct 2, 2026 |
| Oct 1, 2026 | Lockhart Stephen H | AGrant, award, or other acquisition | Common Stock | 304 | $180.85 | Direct | Oct 2, 2026 |
| Oct 1, 2026 | ORLANDO STEVEN J | AGrant, award, or other acquisition | Common Stock | 304 | $180.85 | Indirect | Oct 2, 2026 |
| Oct 1, 2026 | ROMNEY RONNA | AGrant, award, or other acquisition | Common Stock | 304 | $180.85 | Indirect | Oct 2, 2026 |
| Oct 1, 2026 | Schapiro Richard M | AGrant, award, or other acquisition | Common Stock | 304 | $180.85 | Direct | Oct 2, 2026 |
| Oct 1, 2026 | WOLF DALE B | AGrant, award, or other acquisition | Common Stock | 304 | $180.85 | Indirect | Oct 2, 2026 |
| Oct 1, 2026 | ZORETIC RICHARD C | AGrant, award, or other acquisition | Common Stock | 304 | $180.85 | Indirect | Oct 2, 2026 |
| Jul 1, 2026 | ZORETIC RICHARD C | AGrant, award, or other acquisition | Common Stock | 237 | $232.55 | Indirect | Jul 2, 2026 |
| Jul 1, 2026 | WOLF DALE B | AGrant, award, or other acquisition | Common Stock | 237 | $232.55 | Indirect | Jul 2, 2026 |
| Jul 1, 2026 | Schapiro Richard M | AGrant, award, or other acquisition | Common Stock | 237 | $232.55 | Direct | Jul 2, 2026 |
| Jul 1, 2026 | ROMNEY RONNA | AGrant, award, or other acquisition | Common Stock | 237 | $232.55 | Indirect | Jul 2, 2026 |
| Jul 1, 2026 | ORLANDO STEVEN J | AGrant, award, or other acquisition | Common Stock | 237 | $232.55 | Indirect | Jul 2, 2026 |
| Jul 1, 2026 | Lockhart Stephen H | AGrant, award, or other acquisition | Common Stock | 237 | $232.55 | Direct | Jul 2, 2026 |
| Jul 1, 2026 | GROHOWSKI LEO P | AGrant, award, or other acquisition | Common Stock | 237 | $232.55 | Direct | Jul 2, 2026 |
| Jul 1, 2026 | SOISTMAN FRANCIS S JR | AGrant, award, or other acquisition | Common Stock | 237 | $232.55 | Direct | Jul 2, 2026 |
| Jul 1, 2026 | BRASIER BARBARA L | AGrant, award, or other acquisition | Common Stock | 237 | $232.55 | Direct | Jul 2, 2026 |
| Jul 1, 2026 | Bacon Debra | FTax/price withholding or payment | Common Stock | 183 | $232.55 | Direct | Jul 2, 2026 |
| Jun 30, 2026 | WOYS JAMES | AGrant, award, or other acquisition | Common Stock | 144 | $147.51 | Direct | Jul 2, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Jul 22, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jun 10, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| May 27, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| May 11, 2026 | 8-K | 5.02, 5.03, 5.07, 9.01 | Director or executive change; Charter or bylaw change; Shareholder vote results; Financial statements / exhibits | — | Filing |
| May 8, 2026 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Apr 22, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Feb 26, 2026 | 8-K | 7.01 | Regulation FD disclosure | — | Filing |
| Feb 6, 2026 | 8-K | 1.01, 2.03, 2.06, 9.01 | Material definitive agreement; New direct financial obligation; Material impairment; Financial statements / exhibits | Debt | Filing |
| Feb 5, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Nov 20, 2025 | 8-K | 1.01, 2.03, 8.01, 9.01 | Material definitive agreement; New direct financial obligation; Other event; Financial statements / exhibits | Debt | Filing |
| Nov 18, 2025 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
| Nov 17, 2025 | 8-K | 7.01, 9.01 | Regulation FD disclosure; Financial statements / exhibits | — | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $10.9B | -4.8% |
| Ended Mar 31, 2026 | $10.8B | -3.1% |
| Ended Sep 30, 2025 | $11.5B | +11.0% |
| Ended Jun 30, 2025 | $11.4B | +15.7% |
| Period | Revenue | YoY |
|---|---|---|
| Ended Dec 31, 2025 | $45.4B | +11.7% |
| Ended Dec 31, 2024 | $40.7B | +19.3% |
| Ended Dec 31, 2023 | $34.1B | +6.6% |
| Ended Dec 31, 2022 | $32.0B | +15.1% |
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Vanguard Capital Management CIK0002100119 | Jun 30, 2026 quarter end Aug 13, 2026 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 2.4M | $196.93 | |||
| Fidelity / FMR CIK0000315066 | Jun 30, 2026 observed Aug 6, 2026 filed · 37d Schedule 13G amendment | Exit below reporting threshold | 1.9K -1.1K | 3.60% -8.40 pts | $228.70 | $191.88 | $196.93 |
| Vanguard Capital Management CIK0002100119 | Mar 31, 2026 observed Apr 30, 2026 filed · 30d Initial Schedule 13G | Initial Schedule 13G | 2.7M | 5.19% | $133.30 | $194.62 | $196.93 |
Compare MOH with other securities showing similar institutional activity or recent accumulation across several tracked institutions.